Format

Send to

Choose Destination
Curr Rev Musculoskelet Med. 2018 Dec;11(4):624-634. doi: 10.1007/s12178-018-9527-7.

Current Clinical Recommendations for Use of Platelet-Rich Plasma.

Author information

1
Department of Orthopedic Surgery, Stanford University, 450 Broadway St, Redwood City, CA, USA.
2
Lifemark Health Group, Toronto, ON, Canada.
3
Department of Orthopedic Surgery, Stanford University, 450 Broadway St, Redwood City, CA, USA. jdragoo@stanford.edu.

Abstract

PURPOSE OF REVIEW:

This review evaluates current clinical literature on the use of platelet-rich plasma (PRP), including leukocyte-rich PRP (LR-PRP) and leukocyte-poor PRP (LP-PRP), in order to develop evidence-based recommendations for various musculoskeletal indications.

RECENT FINDINGS:

Abundant high-quality evidence supports the use of LR-PRP injection for lateral epicondylitis and LP-PRP for osteoarthritis of the knee. Moderate high-quality evidence supports the use of LR-PRP injection for patellar tendinopathy and of PRP injection for plantar fasciitis and donor site pain in patellar tendon graft BTB ACL reconstruction. There is insufficient evidence to routinely recommend PRP for rotator cuff tendinopathy, osteoarthritis of the hip, or high ankle sprains. Current evidence demonstrates a lack of efficacy of PRP for Achilles tendinopathy, muscle injuries, acute fracture or nonunion, surgical augmentation in rotator cuff repair, Achilles tendon repair, and ACL reconstruction. PRP is a promising treatment for some musculoskeletal diseases; however, evidence of its efficacy has been highly variable depending on the specific indication. Additional high-quality clinical trials with longer follow-up will be critical in shaping our perspective of this treatment option.

KEYWORDS:

Orthobiologics; Osteoarthritis; PRP; Platelet-rich plasma; Regenerative medicine; Tendinopathy

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center